Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Biomarker for the Efficacy and Safety of the Combination of Chemotherapy and Tislelizumab in Non Small Cell Lung Cancer：a Multicentre Prospective Clinical Trial

NCT05244837 is registered in ClinicalTrials.gov with Hao Long as lead sponsor.

NCT NCT05244837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05244837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Biomarker for the Efficacy and Safety of the Combination of Chemotherapy and Tislelizumab in Non Small Cell Lung Cancer：a Multicentre Prospective Clinical Trial
Lead sponsor
Hao Long
Phase
Phase 2
Overall status
Unknown status
Start date
December 22, 2020
Completion date
December 31, 2023
Enrollment
100 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

biomarker, chemotherapy, safety, tislelizumab